Patent intelligence · US
US 8653107
Fentanyl composition for nasal administration
Fentanyl composition for nasal administration
Patent details — US 8653107
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 18, 2014
- Expiration
- Feb 13, 2034
- Applicant
- Takeda Pharma A/S
- Claims
- 25
- CPC classes
- A61K, A61K31/435, A61K31/4468, A61K47/10
Quick answer
US 8653107 (Fentanyl composition for nasal administration) is held by Takeda Pharma A/S. Status: granted. Granted Feb 18, 2014. Expires Feb 13, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Takeda Pharma A/S
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K31/435, A61K31/4468, A61K47/10, A61K47/22, A61K9/0043
More from Takeda Pharma A/S
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 8653107?
US 8653107 (Fentanyl composition for nasal administration) is held by Takeda Pharma A/S. Status: granted. Granted Feb 18, 2014. Expires Feb 13, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8653107?
Takeda Pharma A/S is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 8653107 expire?
Our index shows an expiration date of Feb 13, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.